← Back to screener

ANI PHARMACEUTICALS INC ANIP

Rank #1825 · Nasdaq · $1.8B market cap
Audited by EisnerAmper LLP, no going-concern flag in the latest filing.
Score
41.3
P/E
93.6
P/B
4.36
ROE
4.7%
Op. Margin
9.6%
Debt Ratio
212%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 93.6x, P/B 4.36x. Ranks in the top 61% of the universe.

Profitability ★★☆☆☆
Average

ROE 4.7%. Ranks in the top 52% of the universe.

Safety ★★☆☆☆
Weak

Debt ratio 212%. Ranks in the top 63% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 53.9% year over year. Ranks in the top 7% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B––$0.0B–185
2012$0.0B––$0.0B–155
2013$0.0B$-0.0B$-0.0B$-0.0B-0.2-140
2014$0.0B$0.0B$0.0B$-0.0B3.0-8
2015$0.0B$0.0B$0.0B$-0.0B3.0-280
2016$0.1B$0.0B$0.0B$0.0B35.7306
2017$0.1B$0.0B$0.0B$0.1B42.8110
2018$0.1B$0.0B$0.0B$0.2B15.6148
2019$0.2B$0.0B$-0.0B$0.2B16.0138
2020$0.2B$0.0B$0.0B$0.2B17.5140
2021$0.2B$0.0B$0.0B$0.2B7.9135
2022$0.2B$-0.0B$-0.0B$0.3B-7.7124
2023$0.2B$-0.0B$-0.0B$0.3B-18.4134
2024$0.3B$-0.0B$-0.0B$0.4B-11.2103
2025$0.5B$0.0B$0.0B$0.4B9.6212

← See the full screener